Heron Therapeutics, Inc.
HRTXHealthcare|Biotechnology|US
$0.29
+0.01 (+4.64%)
Tangible Book / Share
$0.04
Cash / Share
$0.22
Clinical Trials (33)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05434663 Safety Study of Repeat Doses of SUSTOL in Adults | Chemotherapy-Induced Nausea and Vomiting (CINV) | P4 | Active | 300 | Open-label | SUSTOL |
| NCT05109312 A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401. | Analgesia | P4 | Active | 90 | RCT, Double-blind | Bupivacaine Hydrochloride, Bupivacaine Hydrochloride, HTX-011, Ibuprofen, Acetaminophen |
| NCT06952868 Boron Neutron Capture Therapy With B10 L-BPA for Unresectable Recurrent Head and Neck Cancers | Head and Neck Cancer, Boron Neutron Capture Therapy | P2 | Recruiting | 24 | Open-label | Drug: B10 L-BPA Injection |
| NCT07003139 A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Malignant Brain Tumors | Malignant Brain Tumors | P1P2 | Recruiting | 10 | Open-label | B10 L-BPA Injection |
| NCT07691775 A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors | Solid Tumor | P1P2 | Recruiting | 30 | Open-label | F18 FBPA Injection |
| NCT07639723 Aprepitant to Improve Same Day Discharge for TKA | PONV | P4 | Not Yet Recruiting | 350 | RCT, Double-blind | Aprepitant Injection, Ondansetron (Zofran), Dexamethasone |
| NCT05863221 ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy | Post Operative Pain, Acute, Bariatric Surgery Candidate | P4 | Unknown | 120 | RCT, Open-label | ZYNRELEF 200Mg-6Mg Extended-Release Solution |
| NCT06109428 Cohort 2 (Abdominoplasty) of: A Multi-surgery Assessment of ZYNRELEF (HTX-011) | Postoperative Pain, Abdominoplasty Surgery | P4 | Completed | 37 | RCT, Double-blind | MMA regimen, HTX-011, Bupivacaine Hydrochloride |
| NCT06109415 Cohort 1 (TSA) of: A Multi-surgery Assessment of ZYNRELEF (HTX-011) | Postoperative Pain, Total Shoulder Arthroplasty | P4 | Completed | 30 | RCT, Double-blind | HTX-011, Bupivacaine Hydrochloride, MMA regimen |
| NCT03705065 Bupivacaine HCl PK and Safety in Augmentation Mammoplasty | Postoperative Pain | P4 | Completed | 30 | RCT, Open-label | Bupivacaine HCl |
| NCT04102267 Extended Delivery of Bupivacaine Study in Herniorrhaphy | Analgesia | P4 | Completed | 32 | RCT, Open-label | Bupivacaine liposome injectable suspension, Bupivacaine HCl without epinephrine via continuous infusion |
| NCT00343460 APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer | Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | P3 | Completed | 1,428 | RCT, Double-blind | APF530, dexamethasone, Palonosetron Hydrochloride |
| NCT02106494 A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC | Chemotherapy-induced Nausea and Vomiting | P3 | Completed | 942 | RCT, Double-blind | APF530, Ondansetron, Ondansetron placebo, APF530 placebo, Fosaprepitant, Dexamethasone |
| NCT03237481 Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2) | Postoperative Pain | P3 | Completed | 418 | RCT, Double-blind | HTX-011, Bupivacaine HCl, Saline placebo |
| NCT03974932 Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen | Analgesia | P3 | Completed | 116 | Open-label | HTX-011, Ibuprofen, Acetaminophen, Celecoxib, +/- Bupivacaine HCl, HTX-011 |
| NCT03907176 Study of Post-Herniorrhaphy Non-opioid MMA Regimens | Analgesia | P3 | Completed | 209 | Open-label | HTX-011, Ibuprofen, Acetaminophen |
| NCT03295721 Bunionectomy Study for Postoperative Analgesia (EPOCH 1) | Postoperative Pain | P3 | Completed | 412 | RCT, Double-blind | HTX-011, Saline Placebo, Bupivacaine HCl |
| NCT03695367 Phase 2 Herniorrhaphy Study for Opioid Elimination | Postoperative Pain | P2 | Completed | 63 | Open-label | HTX-011, Ibuprofen, Acetaminophen, Ketorolac |
| NCT02762929 Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy | Postoperative Pain, Bunions | P2 | Completed | 430 | RCT, Double-blind | HTX-011A, Saline Placebo, HTX-011B, HTX-002, Bupivacaine HCl, HTX-009 |
| NCT02689258 Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery | Postoperative Pain | P2 | Completed | 277 | RCT, Double-blind | HTX-011B, Placebo, HTX-011A, HTX-002, Bupivicaine HCl |
| NCT06668987 A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma | Meningioma, Boron Neutron Capture Therapy | P1P2 | Completed | 10 | Open-label | B10 L-BPA Injection |
| NCT04398329 Dose-Escalation Study of HTX-034 Following Bunionectomy | Bunions, Postoperative Pain | P1P2 | Completed | 78 | RCT, Double-blind | HTX-034 low dose, HTX-034 high dose, Bupivacaine HCl |
| NCT03011333 Phase 2B Upper Extremity Nerve Block Study | Postoperative Pain | P2 | Completed | 243 | RCT, Double-blind | HTX-011, Bupivacaine HCl without epinephrine, Saline Placebo |
| NCT03922048 Pediatric Postoperative Analgesia Herniorrhaphy Study | Analgesia | P2 | Withdrawn | — | RCT, Double-blind | HTX-011, Bupivacaine HCl, HTX-011, HTX-011, HTX-011 |
| NCT02471898 HTX-011 for Post-bunionectomy Analgesia | Analgesia | P2 | Completed | 71 | RCT, Double-blind | HTX-011, Placebo |
| NCT03955211 PK and Safety After C-Section | Postoperative Pain | P2 | Completed | 25 | Open-label | HTX-011, MMA regimen |
| NCT03015532 Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia | Postoperative Pain | P2 | Completed | 285 | RCT, Double-blind | HTX-011, Saline Placebo, Bupivicaine HCl, Ropivacaine |
| NCT02504580 Pilot Herniorrhaphy Study for Postoperative Analgesia | Postoperative Pain | P2 | Completed | 463 | RCT, Double-blind | HTX-011, Placebo, HTX-002, Bupivacaine HCI (Marcaine), HTX-011A, HTX-011B, HTX-009 |
| NCT04085393 Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting | Chemotherapy-induced Nausea and Vomiting | P2 | Withdrawn | — | Open-label | GRANISETRON EXTENDED RELEASE INJECTION (GERSC) |
| NCT03718039 Phase 2 Bunionectomy HTX-011 Administration Study | Postoperative Pain | P2 | Completed | 78 | Open-label | HTX-011, aprepitant |
| NCT04911062 HTX-011 in Spinal Surgery | Post-Operative Pain, Lumbar Laminectomy | P2 | Completed | 32 | Open-label | Bupivacaine HCI without epinephrine, HTX-011 |
| NCT04470622 Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | COVID-19 | P2 | Terminated | 27 | RCT, Double-blind | Aprepitant injectable emulsion, Saline Placebo |
| NCT01416259 A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin | Healthy | Completed | 56 | — | Withdraw treatment |